The MC is pretty full value or a little ahead of itself right now - supported by the fact there is a strong management team and the lead product has a lower risk than most at this clinical trial point. This doesnt stop me from thinking there will be further SP appreciation this year though.
$1B MC prior to FDA approval would be well past overhyped in my opinion.
$1 billion market cap at $1 per share...., page-2
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $501.1M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.5¢ | 33.5¢ | $1.172M | 3.429M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29990 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 174098 | 8 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |